The EAGLE study is a DFG-funded study on early targeted volume therapy of severe acute pancreatitis. The APACHE-II- score was validated as an inclusion criterion and primary endpoint of the EAGLE study based on an interim evaluation of 108 of the planned 182 patients. The APACHE-II-score of ≥ 8 points within 48 hours proved to be a suitable inclusion criterion. As a surrogate parameter of mortality, its increase of ≥ 4 points within 96 hours proved to be a suitable primary endpoint of the study.
«
The EAGLE study is a DFG-funded study on early targeted volume therapy of severe acute pancreatitis. The APACHE-II- score was validated as an inclusion criterion and primary endpoint of the EAGLE study based on an interim evaluation of 108 of the planned 182 patients. The APACHE-II-score of ≥ 8 points within 48 hours proved to be a suitable inclusion criterion. As a surrogate parameter of mortality, its increase of ≥ 4 points within 96 hours proved to be a suitable primary endpoint of the study...
»